[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cvd---cardiovascular-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cvd---cardiovascular-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,43,73,96,122],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100585916","community-health-worker-led-intervention-to-increase-cardiac-rehabilitation-participation-100585916",false,"NCT06908590","Community Health Worker-Led Intervention to Increase Cardiac Rehabilitation Participation","Heart-to-Heart: A Community Health Worker-Led Intervention to Increase Cardiac Rehabilitation Participation Among Patients With Low Socioeconomic Status","H2H","Inclusion Criteria:\n\n1. Patients hospitalized with cardiac events and eligible for CR at Johns Hopkins Hospital and Bayview Medical Center. CR eligibility is determined by their treating health care team .\n2. Low socioeconomic status defined by Medicaid insurance, or top quartile of the area deprivation index in Baltimore city.\n3. Age ≥ 21 years\n4. Willing to be audio-recorded\n\nExclusion Criteria:\n\n1. Formal diagnosis of dementia or cognitive impairment in the Electronic Health Record (EHR) that would prohibit completion of study activities\n2. Formal diagnosis of a severe psychiatric disorders by Diagnostic and Statistical Manual (DSM-5) criteria in the EHR that would prohibit completion of study activities (e.g., schizophrenia, schizoaffective disorder, bipolar disorder, major depressive disorder).\n3. Systemic illness limiting longevity (e.g., advanced cancer)\n4. Contraindications to CR as assessed by their health care team\n5. Unwilling or unable to follow study procedures.\n6. Unable to consent\n7. Unable to speak or understand English. Assessments including in-depth interviews will be conducted in English.","ALL","21 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study is being done to evaluate whether a program called Heart to Heart, that helps patients make a more informed decision about cardiac rehab (CR), is interesting, acceptable to participants, and whether participants would recommend it to others.",[27],"CVD - Cardiovascular Disease",[29],"cardiac rehabilitation","RECRUITING","2026-02-25",{"date":33,"type":34},"2026-02-27","ACTUAL",{"date":36,"type":34},"2026-02-19",{"date":38,"type":21},"2027-07-01",{"name":40,"class":41},"Johns Hopkins University","OTHER",3,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":60,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100620504","delphi-procedure-for-developing-recommendations-for-the-implementation-of-wearable-devices-and-polygenic-risk-scores-100620504","NCT07358481","DELphi Procedure for Developing Recommendations for the Implementation of Wearable Devices and Polygenic Risk Scores","DEL-DIP: DELphi Procedure for Developing Recommendations for the Implementation of Wearable Devices and Polygenic Risk Scores","DEL-DIP","Inclusion criteria\n\n* Experts in cardiology\n* Experts in personalized medicine\n* Experts in digital health.\n\nExclusion criteria\n\n\\- Failure to provide informed consent (i.e., non-acceptance of the informed consent form)",true,{"count":53,"type":21},10,"OBSERVATIONAL","DEL-DIP is a prospective observational study employing a Delphi methodology (at least two online rounds) to elicit and consolidate the views of an expert panel within the INNOPREV project. The study aims to develop operational recommendations to support the coordinated implementation of Polygenic Risk Scores (PRS) and wearable devices in cardiovascular prevention. Specifically, it addresses the following research question: which recommendations and requirements-genomic, digital, and clinical\u002Forganizational-are necessary to integrate PRS and wearable technologies into routine practice and healthcare services, and for which of these elements do experts achieve consensus (defined as a Content Validity Index, CVI, \\> 79%)",[57,58,27,59],"Wearable Electronic Devices","Polygenic Risk Score","Primary Prevention",[61],"cardiovascular prevention","NOT_YET_RECRUITING","2026-01-22",{"date":65,"type":34},"2026-01-23",{"date":67,"type":21},"2026-02",{"date":69,"type":21},"2026-04",{"name":71,"class":41},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":72},"100615869","corazones-unidos-study-100615869","NCT07298213","Corazones Unidos Study","Pilot Test of Su Corazon Su Vida Among Mexican Origin Adults With MASLD","Inclusion Criteria:\n\n* Eligible intervention participants must (1) be Mexican-origin\u002FMexican decent, (2) be ≥ 18 years old, (3) have a confirmed MASLD diagnosis (CAP score of ≥ 248 dB\u002Fm); (4) have an adult member of their social network who might be interested in participating in the study and who lives within 25 miles of the participant's residence; (5) be able to provide informed consent; and (6) be able to speak, read, and write in English and\u002For Spanish. Eligible social support participants must (1) be ≥ 18 years old, (2) be first degree blood relative or spouse\u002Fsignificant other to the intervention participants, (3) be able to provide informed consent; and (4) be able to speak, read, and write in English and\u002For Spanish.\n\nExclusion Criteria:\n\n* Exclusion for individuals interested in the intervention component of the study will be excluded if they report (1) ongoing or recent alcohol consumption (≥21 standard drinks on average per week in men and ≥14 standard drinks on average per week in women); (2) previous diagnosis of liver cancer; (3) taking any anti-inflammatory or hepatoxic medication regularly; (4) taking medication for any form of psychiatric disorders; (5) diagnosis of depression; (6) diagnosis of autoimmune disorders; or (7) women who are pregnant or breastfeeding due to hormonal changes. Exclusion for those interested to be part of the study as social network participants will not be considered for participation if they (1) live more than 25 miles of the intervention participant's residence.","18 Years",{"count":82,"type":21},45,[24],"CVD is the leading cause of death among individuals with MASLD, a risk factor for liver cancer. In Southern Arizona, CVD and cancer (including liver and gastric cancer) are among the leading causes of death for Mexican-origin adults.1 Given Mexican-origin adults' disproportionate burden of CVD-related mortality37 and higher rates of MASLD compared to other ethnic\u002Fracial groups; we urgently need to develop contextually tailored strategies for management of CVD risk factors and outcomes. Thus, the purpose of this study is to examine the acceptability and feasibility of a community health worker (CHW)-led intervention aimed to increase cardiovascular risk awareness and promote lifestyle modifications among Mexican-origin adults with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in the Southern Arizona region. The proposed project has the potential to improve health outcomes for this vulnerable population and contribute to the ACS-CHERC's overarching goal of improving health equity for Hispanic communities and family caregivers.",[27,86],"MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease","2025-12-11",{"date":89,"type":34},"2025-12-23",{"date":91,"type":34},"2025-07-18",{"date":93,"type":21},"2026-07-17",{"name":95,"class":41},"University of Arizona",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":80,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":111,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":72},"100575736","the-effect-of-standardizing-procedures-for-sc-injections-of-lmwh-on-patients-with-cvd-100575736","NCT06776159","The Effect of Standardizing Procedures for SC Injections of LMWH on Patients With CVD","The Effect of Standardizing Procedures for Subcutaneous Injections of Low-molecular-weight Heparin on Patients With Cardiovascular Diseases: A Cluster Randomized Controlled Trial","LMWH","Inclusion Criteria:\n\n* patients who are in cardiac care units suffering from cardiovascular diseases prescribed with LMWH injections two times per day\n* Chinese\n\nExclusion Criteria:\n\n* cognitively impaired\n* unconscious\n* refuse to participate",{"count":105,"type":21},180,[24],"Improper subcutaneous administration of LMWH may cause complications at the injection site. Standardized protocol for subcutaneous LMWH injections in patient with cardiovascular diseases is warranted to ensure consistent best practices in clinical settings.",[27,109,110],"Bruise","Pain",[112],"LMWH injection","2025-09-10",{"date":115,"type":34},"2025-09-11",{"date":117,"type":34},"2025-06-24",{"date":119,"type":21},"2026-01-31",{"name":121,"class":41},"The Hong Kong Polytechnic University",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":129,"minAge":80,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":72},"100597642","a-potential-relationship-between-treatment-with-tyrosine-kinase-inhibitors-and-erectile-dysfunction-in-male-patients-with-chronic-myeloid-leukemia-100597642","NCT07061145","A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid Leukemia","ED2024","Inclusion Criteria:\n\n* Patients diagnosed with chronic phase Philadelphia chromosome-positive (Ph+) and\u002For BCR-ABL-positive CML.\n* Patients starting frontline treatment with TKIs between 01st January 2015 and 31st January 2022.\n* Age greater than or equal to 18 years and not exceeding 75 years at the time of starting therapy.\n* Male sex.\n* Exposure to Hydroxyurea or Anagrelide before the initiation of TKI therapy is allowed\n* Ability to provide informed consent, as demonstrated by a clear understanding of the study's objectives and procedures and the ability to make an informed and voluntary decision to participate\n* Signed written informed consent according to ICH\u002FEU\u002FGCP and national and local laws.\n\nExclusion Criteria:\n\n* Patients with advanced phases (accelerated or blastic phase) Ph+ and\u002For BCR-ABL+ CML\n* Patients who experienced ED before TKI initiation","MALE","75 Years",{"count":132,"type":21},350,"Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the presence of the Philadelphia chromosome, resulting in the constitutive activation of the BCR-ABL1 tyrosine kinase. The advent of tyrosine kinase inhibitors (TKIs) has revolutionized the management of CML, trasforming it from a fatal disease to a chronic condition with excellent long-term outcomes for the majority of patients. The introduction of tyrosine kinase inhibitor (TKI) based treatment for CML has revolutionized the management of this previously fatal disease, achieving sustained disease-control in more than 90% of patients.\n\nHowever, as patients with CML are often required to undergo lifelong TKI therapy to maintain disease control, concerns regarding the long-term safety and tolerability of these agents have emerged.\n\nThe efficacy of second and third-generation TKIs exceeds the efficacy of imatinib, owing to their potent impact on wild-type BCR-ABL1 and various BCR-ABL1 mutants, along with additional drug targets. Furthermore, TKIs exhibit activity on non-kinase targets (es. oxidoreductase NQO2 for nilotinib and imatinib).\n\nThe prolonged treatment duration and expanded TKIs repertoire have led the emergence of various unexpected non-hematologic adverse events (AE), notably vascular adverse events (VAEs).\n\nRecent evidence indicates a relatively high incidence of severe arterial changes in TKI-treated patients, with VAEs frequency correlating with TKI dosage and treatment duration. However, data elucidating the clinical features of vascular events are lacking.\n\nHormonal alterations have been reported in patients treated with imatinib. The tyrosine-kinase receptors cKIT and PDGF receptors, along with their respective ligands, are expressed in the testis, where they play a role in stimulating testosterone secretion by Leydig cells. Prolonged imatinib use has been associated with reduced testosterone production due to PDGFR and cKit blockade in the testis, potentially leading to gynaecomastia in men.\n\nCardiovascular disease (CVD) remains the leading cause of mortality in the United States, accounting for nearly 40% of all deaths. CVD and ED share a variety of common risk factors, including hypertension, diabetes, dyslipidemia, smoking, obesity, physical inactivity, and metabolic syndrome. Screening and diagnosing ED hold significant potential for secondary prevention of CVD. Despite the estabilished association between ED and CVD, the precise mechanisms driving ED's predictive value for CVD are yet to be fully identified. Early deection and treatment of CVD during the critical time frame in which risk factors can be modified will effectively reduce the occurrence of fatal CV events in male patients with ED.\n\nThis is a multicentre national, retrospective, prospective, non-interventional study that focuses on male CML patients starting first-line treatment with TKIs between 1 January 2015 and 31 January 2022.\n\nAll enrolled patients will be involved in both retrospective and prospective evaluations.\n\nThe retrospective component of the study allows the collection of data on the onset of ED, documented in medical records, that occurred before enrolment. It also includes information from physical examinations and laboratory tests, such as complete blood count, serum biochemistry (including renal and liver function tests, lipid profile and glycosylated haemoglobin), molecular biology for BCR-ABL transcript levels and electrocardiography (ECG), collected retrospectively every six months from enrolment until the documented onset of ED. The prospective evaluation assesses the occurrence of ED in the six months prior to enrolment and during the two-year follow-up period.\n\nThe primary objective of the study is to assess the incidence of erectile dysfunction (ED) among male patients with chronic myeloid leukaemia (CML) undergoing treatment with tyrosine kinase inhibitors (TKIs), imatinib, dasatinib, nilotinib, bosutinib or ponatinib, focusing in particular on those individuals who report the appearance of associated symptoms after treatment.",[135,136,27,137],"Chronic Myelocytic Leukemia","Erectile Dysfunctions","Tyrosine Kinase Inhibitor","2025-08-05",{"date":140,"type":34},"2025-08-06",{"date":142,"type":34},"2025-07-01",{"date":144,"type":21},"2028-12",{"name":146,"class":147},"Azienda USL Reggio Emilia - IRCCS","OTHER_GOV"]